Articles

Papers, explained in our own words

Every entry summarises what the study set out to test, what it found and why it changes how we design delivery systems. Browse research and reviews or search the collection.

391 articles

Keyword: Silica nanoparticlesClear keyword

Materials Science and Engineering: C2021ResearchDrug Delivery

1. Microfluidic preparation of PLGA composite microspheres with mesoporous silica nanoparticles for finely manipulated drug release

Jiayu Zhou, Yishu Zhai, Jumei Xu, Tian Zhou, Lian Cen

PLGA microspheres are widely used for controlled drug release, but they often exhibit pronounced initial or mid-term burst release. A strategy is needed to finely tune drug release kinetics and suppress burst release, especially for water-soluble drugs. MSNs: Average size 119 nm; specific surface area 902.53 m²/g; pore volume 1.15 cm³/g; mean pore diameter 5.09 nm; maximum RB loading ~110 mg/g. - MSN-RB release: ~95% cumulative release within 56 h; Korsmeyer–Peppas n =.

PLGA Nanoparticles Silica nanoparticles Polymeric Microfluidics Nanocarriers Gene delivery

Read the article

Proceedings of the National Academy of Sciences (PNAS)2020ResearchNon-viral Gene Delivery

2. Ultrasmall silica nanoparticles directly ligate the T cell receptor complex

Bradley Vis, Rachel E. Hewitt, Tom P. Monie, Camilla Fairbairn, Suzanne D. Turner, Stephen D. Kinrade, Jonathan J. Powell

Ultrasmall silica nanoparticles (USSN, <10 nm diameter) were recently shown to stimulate T lymphocytes directly at relatively low exposure doses, but the underlying mechanisms and associated cell signaling were unknown. Understanding whether USSN directly engage the T cell receptor (TCR) complex or act through other pathways is critical for both safety assessment and therapeutic translation of these inexpensive, rapidly dissolving nanoparticles. ### USSN Activation of T Cells (CD69 Expression, 24 h) | Cell Type | Control (%) | USSN (800 μM) (%) | Fold Increase | |---------------|-----------------|-----------------------|------------------| | CD4⁺ T cells (n=23).

T cells Nanoparticles TCR signaling Silica nanoparticles Biodistribution Immune cells Nanocarriers

Read the article

Let's engineer the next delivery breakthrough together

We co-develop nanocarrier and biosensing programs with pharma, biotech and academic groups — from target selection through GMP supply.

Start a conversation Explore the pipeline